The Latest

Dolutegravir Preconception Signal: Time Is Up for Shoddy Surveillance

"It is hard to imagine how in 2018 we could be in this situation where women with HIV are being so woefully underserved," Polly Clayden writes.

By Polly Clayden for HIV i-Base

Integrase Inhibitors and Their Effectiveness and Safety in Women

Results from two studies show that not only do integrase inhibitor-based regimens work well in women, but that they better tolerated than a regimen based on the protease inhibitor atazanavir.

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange

Dolutegravir in Women

In the Aria study, Triumeq showed statistical superiority over an atazanavir-containing regimen at 48 weeks in HIV-positive women.

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange

Dolutegravir Is Superior to Boosted Atazanavir in Women in the ARIA Study

Dolutegravir-based ART was superior to a boosted atazanavir-based regimen in treatment naive women at 48 weeks, according to data from the ARIA study presented at AIDS 2016.

By Polly Clayden for HIV i-Base

Dolutegravir Superior in Women-Only Study

On behalf of IFARA, Fred Schaich spoke with Kimberly Smith of ViiV Healthcare at this year's International AIDS Conference about 48-week data from the ARIA study of drug efficacy in women with HIV.

By Barbara Jungwirth